AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.59+0.32 (+2.84%)
Close on Oct 19, 2026
- Market cap
- $505.35M
- P/E (TTM)
- –
- Dividend yield
- –
Avalo Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $59.00K | $441.00K | $1.41M | $3.36M | $4.77M | $6.70M | $6.70M | – | – | 100.0% | -86.6% |
| Grant revenue | – | – | – | – | – | – | – | $0 | $624.57K | – | – |
| Prescribed dietary supplements | – | – | – | – | – | – | – | $7.68M | $1.09M | – | – |
| Prescription drugs | – | – | – | – | – | – | $6.65M | $6.57M | $818.13K | – | – |
| Sales force revenue | – | – | – | – | – | – | $0 | $456.06K | $278.17K | – | – |
| Product revenue, net | – | – | – | – | – | – | $6.65M | $6.57M | $1.91M | – | – |
| License revenue | – | $0 | $516.00K | $14.69M | $625.00K | $0 | $100.00K | $0 | $25.00M | – | – |
| AVTX-611 | – | – | – | $200.00K | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Avalo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.